

IMPACT OF BIOLOGIC AND IMMUNOMODULATORY THERAPY ON SARS-COV-2 INFECTION AND IMMUNITY IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE.

CLARITY Extension Parent/Guardian Participant Information Sheet

Thank you for taking the time to read this leaflet. Your child is being invited to continue in the CLARITY IBD study for an additional 24 weeks. Before you decide whether you would like your child to take part, it is important that you understand why the research is being done and what it will involve. Please take time to read the following information carefully. Ask us if there is anything that is not clear, or if you would like more information.

What is the purpose of the study?

Results from the CLARITY IBD study have shown that use of infliximab is associated with lower antibody levels following COVID-19 infection and after COVID-19 vaccination. Further work is needed to investigate whether antibody levels fall over time and whether they can be restored with additional vaccine doses. The results of this study will help inform public health policy decisions for patients with IBD as well as millions of other UK patients treated with immunosuppressive drugs.

Why have I been asked to participate?

Your child has been invited to participate because they are already a participant in the CLARITY IBD study and continue to receive infliximab or vedolizumab.

Do I have to take part?

It is up to you to decide whether to continue to take part. If you do decide they will take part, you will still be free to withdraw at any time and without giving a reason. This would not affect the standard of care your child receives.

What will happen to me if I agree to take part?

We will first ask you to give consent for your child to participate in this extension phase of the study. To do this an email will be sent to you with a personalised link. You will then be asked to enter your child's surname and date of birth to confirm your child's identity before completing the e-consent form.

Your child will be asked to continue to complete a questionnaire and give a blood sample every 8 weeks. If your child is not attending the hospital regularly then a blood sample can be taken at home using the Exeter home finger prick test kit.

What will happen to the blood sample?

Your child's blood sample will be given a code number so that their identity will not be revealed to anyone outside of your local hospital, and if you agree, the data controller at the Royal Devon and Exeter Hospital. It will be sent to the Royal Devon and Exeter Hospital for a test to see if they have antibodies to SARS-CoV-2.

IMPACT OF BIOLOGIC AND IMMUNOMODULATORY THERAPY ON SARS-COV-2 INFECTION AND IMMUNITY IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE.

CLARITY Extension Parent/Guardian Participant Information Sheet

Your child's blood samples will be considered a gift to the Exeter Clinical Research Facility and will be transferred to the Peninsula Research Bank. A steering committee will approve the use of these samples for future research. This research may form part of collaborations in the UK or overseas including collaborations with companies. Specifically, samples:

- a) will not be sold for profit
- b) will not be used in animal research
- c) will not be used in research into the termination of pregnancy or reproductive cloning
- d) will not be screened for genes directly predictive of rare disease (e.g. Huntington's)
- e) will not be shared with non-research organisations

What will happen to the results of the study?

At the end of the study we will publish the results of this research and will be happy to provide you with a copy of the publication if you request it. Your child will not be identifiable in this publication.

Are there any benefits from taking part in this study?

There are no benefits to individual participants from taking part. However, this study will help inform public health policy, by determining how immunosuppressive drugs impact SARS-CoV-2 infection risk and subsequent immunity from infection or vaccination.

We will return your child's SARS-CoV-2 antibody test result to you and your local team.

If I participate will my personal medical information be kept confidential?

We will need to continue collecting information from your child's medical records for this research project. In addition, we will need access to your child's name, date of birth, postcode, email address, mobile number, and NHS number. Your child's name, date of birth, email and mobile phone numbers are required so that you can receive electronic links to the consent form and questionnaires. Your child's NHS number is required to allow linkage with research datasets held by Public Health England and NHS Digital. Your local hospital will pass these details to the Royal Devon and Exeter NHS Foundation Trust along with the information collected from you and your child's medical records.

We will keep all information about your child safe and secure. The Royal Devon and Exeter Hospital NHS Foundation Trust is the data controller. Access to your child's identifiable data will be restricted to the research team at your hospital and individuals at the Royal Devon and Exeter Hospital NHS Foundation Trust, nominated by the data controller, who have received appropriate training in handling personal data. Your child's personal data will be removed before it is made available to members of the central research team. Data from the study will be kept for up to 5 years but the

IMPACT OF BIOLOGIC AND IMMUNOMODULATORY THERAPY ON SARS-COV-2 INFECTION AND IMMUNITY IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE.

CLARITY Extension Parent/Guardian Participant Information Sheet

identifiable information, linking this to your child, will be removed as soon as the study has been finished.

Your rights to access, change or remove your child's information are limited, as we need to manage your child's information in specific ways in order for the research to be reliable and accurate. Your child can stop being part of the study at any time, without giving a reason, but we will keep information about your child that we already have collected.

We will write our reports in a way that no-one can work out that your child took part in the study. For further information on how we use your child's data you can email rde-tr.clarityibd@nhs.net or <http://www.hra.nhs.uk/patientdataandresearch>

What if I have a complaint or concerns about the study?

Whether or not you take part in the study, if you wish to complain, or have any concerns about any aspect of the way you have been approached or treated during the course of this study, the normal National Health Service complaints mechanisms would be available to you. Taking part in the study would not affect your legal rights.

Who is conducting the research?

This study is being carried out by a group of Gastroenterologists and scientists from the Royal Devon and Exeter Hospital, Imperial College, London and Hull Royal Infirmary. The central study office is at the Royal Devon and Exeter Hospital. The investigators are not being paid to carry out this work.

Who has reviewed the study?

All research in the NHS is looked at by an independent group of people called a Research Ethics Committee to protect your safety, rights, wellbeing and dignity. This study has been reviewed and given favourable opinion by London-Surrey Borders Research Ethics Committee.

Who is organising and funding the research?

This study is funded by Roche, Takeda, Biogen, Galapagos, Celltrion, the Royal Devon and Exeter NHS Foundation Trust and Hull University Teaching Hospital NHS Trust. It is supported by the National Institute for Health Research Clinical Research Network (NIHR CRN).

The sponsor of the research is the Royal Devon and Exeter NHS Foundation Trust. The sponsor may decide to stop the study at any time and if this happens the reasons will be explained to you. This will not affect your child's on-going clinical care. Any anonymised data that has been collected up until this time point will be used for analyses.

I have some further questions, who can I ask?

IMPACT OF BIOLOGIC AND IMMUNOMODULATORY THERAPY ON SARS-COV-2 INFECTION AND IMMUNITY IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE.

CLARITY Extension Parent/Guardian Participant Information Sheet

You can find further information at this website www.clarityibd.org and by contacting the team below:

Chief Investigator:

Dr Tariq Ahmad

Consultant Gastroenterologist

Royal Devon and Exeter Hospital NHS FT

Email: rde-tr.clarityibd@nhs.net